Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Acquisition
SEC Form 4 Filing
Robert Andrade, CFO of Fennec Pharmaceuticals, reports the acquisition of 1,042 common shares on October 31, 2024.
Summary
- Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction on October 31, 2024.
- Andrade acquired 1,042 common shares at a price of $0.
- Following the transaction, Andrade beneficially owns 111,565 common shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing reporting a share transaction. The acquisition itself could be seen as mildly positive, but the filing is primarily informational.
Positives
- The acquisition increases Andrade's stake in the company, potentially signaling confidence in its future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The increased ownership by a key executive could be viewed positively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 2023-03-31 | Date of original share award. |
| 2024-10-31 | Date of transaction: Acquisition of 1,042 common shares. |
| 2024-11-04 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.